Publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Issued Date
2019-10-01
Resource Type
ISSN
15326535
00099236
00099236
DOI
Other identifier(s)
2-s2.0-85068533591
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Pharmacology and Therapeutics. Vol.106, No.4 (2019), 726-733
Suggested Citation
Zeruesenay Desta, Roseann S. Gammal, Li Gong, Michelle Whirl-Carrillo, Aditya H. Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan Myers, Marelize Swart, Rachel F. Tyndale, Collen Masimirembwa, Otito F. Iwuchukwu, Sanika Chirwa, Jeffrey Lennox, Andrea Gaedigk, Teri E. Klein, David W. Haas Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics. Vol.106, No.4 (2019), 726-733. doi:10.1002/cpt.1477 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51406
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Other Contributor(s)
Fairleigh Dickinson University
University of Texas Health Science Center at Houston
Meharry Medical College
Indiana University School of Medicine Indianapolis
Cleveland Clinic Foundation
St. Jude Children's Research Hospital
University of Toronto
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Massachusetts College of Pharmacy and Health Sciences
Stanford University
Vanderbilt University School of Medicine
Emory University School of Medicine
Division of Clinical Pharmacology
Wilkins Hospital
University of Texas Health Science Center at Houston
Meharry Medical College
Indiana University School of Medicine Indianapolis
Cleveland Clinic Foundation
St. Jude Children's Research Hospital
University of Toronto
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Massachusetts College of Pharmacy and Health Sciences
Stanford University
Vanderbilt University School of Medicine
Emory University School of Medicine
Division of Clinical Pharmacology
Wilkins Hospital
Abstract
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.